| Predicate |
Object |
| contentType |
Comment|Journal Article |
| endingPage |
41 |
| issn |
1356-5524 |
| issueIdentifier |
2 |
| pageRange |
40-41 |
| publicationName |
Evidence-Based Medicine |
| startingPage |
40 |
| bibliographicCitation |
Davis WA. Cost-effectiveness analysis: Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169,572 per QALY and exenatide with $278,935 per QALY as second-line treatment in adult diabetics in the USA. Evid Based Med. 2010 Apr;15(2):40–1. doi: 10.1136/ebm1034. PMID: 20436114. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c189dbca9aece6be14b8fe4ef12742e6 |
| date |
2010-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/20436114
https://doi.org/10.1136/ebm1034 |
| isPartOf |
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/32137
https://portal.issn.org/resource/ISSN/1356-5524 |
| language |
English |
| source |
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
Cost-effectiveness analysis: Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169,572 per QALY and exenatide with $278,935 per QALY as second-line treatment in adult diabetics in the USA |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53396299
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45588096
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3488
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID138394057
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4369359
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56927919
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7440 |